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There are two strong arguments for including a
doctor, preferably a surgeon, on the inquiry: under›
standing and credibility. Juries include no experts, yet
sit in judgment on the most complex and awful
crimes—but this is no crime. Those who put their
fingers into the hearts and brains of others to try and
save their lives are qualitatively different from those
who don’t: it requires a special kind of courage and a
mixture of compassion and detachment that most find
difficult to muster. Only another surgeon can
understand fully the difficulties that the Bristol
surgeons faced.
To succeed in its mission to understand, explain,
and improve the public inquiry will have to command
the credibility of all parties. The GMC clearly failed, as
views expressed in this issue show (p 1579, 1592),13 14
and the inquiry may have an almost impossible
task—because it starts in a climate of deep division and
bitterness. The inquiry will lose the credibility of many,
probably most, doctors if it starts without a doctor on
the panel. The difficult challenge is to find a doctor who
is not seen as a stooge of the establishments of either
medicine or the Department of Health.
Meanwhile, the government and the medical
profession want to restore the public’s confidence in
the competence of doctors and the quality of care
within the NHS. They must achieve this against a flood
of adverse media reports, which makes careful thought
difficult and increases the pressure to do something, no
matter how hasty and ill considered.
What might the perfect system look like? One long
philosophical tradition, represented best perhaps by
Thomas Hobbes, believes that people are essentially
bad and need to be tightly regulated to stop them
doing ill. Another tradition, represented by John
Locke, believes that people perform best if trusted,
given space and resources, and essentially left to their
own devices. Hobbesians might favour government
control of doctors, Lockeians self regulation. Probably
a mix is needed and a wider concept of self regulation
that includes good management.15 Perhaps we are
headed in the right direction with a re›energised GMC
with heavy lay representation and the new systems of
clinical governance. The danger is, however, that it’s all
too much and too confused. Doctors now face
revalidation, compulsory continuing medical educa›
tion and audit, governance of their clinical activity by
their trust or primary care group, peer review, and a
possible visit from a hit squad from their college or
from the Commission for Health Improvement. The
dangers are that their internal motivation (the most
important thing) is crushed, that their time is diverted
into activities that are more bureaucratic than
beneficial to patients, and that they resort to game
playing to buck the system (something at which
doctors are highly skilled). Out of this muddle doctors
and politicians must produce a more coherent system
of regulation and governance that is credible to both
patients and doctors.
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The end of the heparin pump?
Low molecular weight heparin has many advantages over unfractionated heparin
Antithrombotic therapy with intravenous unfrac›tionated heparin has been the mainstay ofearly treatment of patients with venous
thromboembolic disease and unstable angina. On a
typical medical ward several patients will be attached to
syringe drivers containing heparin. Management of
these patients is time consuming: heparin infusions
have to be made up daily, intravenous cannulas resited,
blood samples analysed for monitoring of coagulation
control, and doses adjusted on the basis of these
results. The potential for dosing errors is high: even in
trials with criteria for dose monitoring, over 60% of
patients are overanticoagulated or underanticoagu›
lated 24 hours after the start of heparin therapy.1
Newer low molecular weight heparins are much easier
to administer, but do they have other advantages over
unfractionated heparin?
The benefit of heparin treatment to patients with
venous thromboembolic disease and unstable angina
has been shown in several trials. In the only placebo
controlled trial of heparin in pulmonary embolism the
mortality rate was so much lower in treated patients
that the trial was stopped.2 In unstable angina several
randomised trials have indicated a trend towards
reduced risk of death and non›fatal myocardial infarc›
tion in patients treated with aspirin and heparin com›
pared with aspirin alone. A meta›analysis of these trials
indicated a relative risk reduction of 33% with
combined aspirin and heparin in patients whose abso›
lute risk of death or myocardial infarction is 14% in the
first three months.3
Conventional unfractionated heparin refers to a
family of mucopolysaccharides of varying chain
length and composition which are not separated into
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their component parts. Heparin forms a high affinity
complex with antithrombin III, which inhibits
thrombin and activated factors X, IX, and XI, depend›
ing on the chain length of the heparin molecule.
Unfractionated heparin has an antifactor Xa:anti›
thrombin ratio of 1:1. Over the past decade a family of
low molecular weight heparins has been developed,
based on the principle that inhibiting the earlier
amplification stages of the coagulation cascade will
provide more effective anticoagulation. These mol›
ecules have an antifactor Xa:antithrombin ratio of 2:1
to 4:1. Low molecular weight heparins have several
other theoretical therapeutic advantages: higher
bioavailability after subcutaneous injection, longer
half life, and a lower propensity to induce thrombocy›
topenia. Haemorrhagic complications may also be
reduced because, in contrast with unfractionated
heparin, low molecular weight heparins have lower
affinity for von Willebrand factor, have a weaker
inhibitory effect on platelet function, and are less
prone to increasing vascular permeability. Their high
bioavailability and antifactor Xa activity confer a
predictable dose response, which allows administra›
tion on a per kilogram basis without the need for rou›
tine anticoagulation monitoring. Indeed, most prepa›
rations can be administered by weight adjusted twice
daily injection.
But are these preparations as effective as unfrac›
tionated intravenous heparin? Trial evidence is
accumulating that they are. In patients with unstable
angina or non›Q wave myocardial infarction, the FRIC
and ESSENCE studies showed, respectively, that
dalteparin and enoxaparin are at least as effective as
unfractionated heparin at preventing death, myocar›
dial infarction, and recurrent angina.4 5 Neither study
used anticoagulant monitoring in patients receiving
the low molecular weight preparation, and there was
no difference between groups in the incidence of
major and minor haemorrhagic complications. How›
ever, no trial evidence currently exists to support the
use of low molecular weight heparins as an adjunct to
thrombolysis.
Low molecular weight heparins are effective in
treating venous thromboembolic disease. In a study of
432 patients with proximal deep venous thrombosis
intermittent subcutaneous logiparin substantially
reduced the incidence of death and major haemor›
rhage compared with intravenous unfractionated
heparin.6 Similar results are seen with fraxiparine;
enoxaparin and dalteparin are at least as safe and
effective as unfractionated heparin.7 Furthermore,
patients can be taught to administer low molecular
weight heparins at home, and there are clear economic
advantages in reducing the time in hospital.8 9 Finally,
subcutaneous tinzaparin has recently been shown to be
as safe and effective as unfractionated heparin in
managing the early phase of acute pulmonary
embolism in hospital.10
The practical advantages of low molecular weight
heparins are less compelling for thromboembolism
prophylaxis, since in this setting unfractionated
heparin is also administered subcutaneously and anti›
coagulant monitoring is not required. However, a
recent meta›analysis of 22 trials of low molecular
weight heparins for prophylaxis against venous
thromboembolism in orthopaedic surgery showed
that they are better and safer than unfractionated
heparin and warfarin.11 In some high risk settings,
for example after major trauma, low molecular weight
heparins may be better than unfractionated
heparin.12
Although low molecular weight heparins are more
expensive than unfractionated heparin, cost savings
are likely through savings in consumables and staff
time. Their economic impact must also be assessed in
terms of the effect on complications of unstable angina
and the cost of subsequent procedures: a cost benefit
analysis from the United Kingdom subgroup in the
ESSENCE study estimated savings of over £2300 per
100 patients treated with enoxaprin.13
Caution is clearly needed when considering practi›
cal procedures such as arterial sampling or central
venous line insertion in patients treated with low
molecular weight heparin—no infusion pump is
present as a reminder that the patient is receiving anti›
coagulant therapy. Furthermore, guidelines need to be
established for safe timing of arterial sheath removal
after coronary angiography and intervention in
patients treated with low molecular weight heparin.
Also, important differences exist in the properties of
the different preparations: they are not interchange›
able, and regimens proved in trials should be used for
those specific clinical applications. Moreover, in certain
circumstances it is sensible to use intravenous heparin
because it can be discontinued abruptly—for example,
in patients with mechanical valves undergoing surgery
or in patients at high risk of bleeding. Nevertheless, and
with these caveats, it is time to abandon the heparin
pump for the prophylaxis and treatment of venous
thromboembolic disease and for managing patients
with unstable angina.
Neil R Grubb Lecturer in cardiology
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Clinical futures
Are as important to health policy as economic and social futures
Speculation about the future of medicine oftencentres on anticipated or imagined break›throughs in science and technology and on the
possible impact of these advances in preventing and
treating disease. Yet much of the thinking about health
policy has stemmed from the perspectives of political,
social, economic, legal, and organisational theory. It is
time to move the two closer together.
This week sees the publication of a book of essays
by a number of distinguished clinical investigators who
were invited to take a freewheeling look at the likely
trends in diagnosis and treatment over the coming
decades.1 Our concern in undertaking this exercise was
to redress a balance and to create a forum for the
strategic thinking of clinicians and others engaged in
pushing forward the boundaries of medical science
and services.
Doctors, and particularly clinical innovators, have
not suffered from a lack of critics from both within and
without the profession. Zola, for example, lamented the
“medicalisation” of society2 and Illich doctors’ “expro›
priation” of health.3 In all this there is evidence of a
fashionable cynicism about the good intentions of
medical (and other) scientists, grafted on to a historical
distrust of a powerful profession. These attitudes are
echoed in public policy. In the past decade many of the
shortcomings of the NHS have been blamed on the
enthusiasm of doctors for biotechnical innovation.
Indeed, the internal market was introduced largely to
reclaim the service from such “provider capture.”
The likely scale of medical advance over the
coming decades is such that the role of the doctor will
need to change radically in response to new technolo›
gies and new demands. However, too little attention
has been given to the nature of the metamorphosis
that will be necessary to prepare the medical
profession for the future or to the contribution that
medicine could make to shape society.
The term “medicine” covers an ever widening set of
activities as diverse as the functioning of health action
zones, stereotactic neurosurgery, and forensic psychia›
try. We share with many the conviction that there are
important core values that link such kaleidoscopic
elements of medical practice and that these need to
amount to more than professional self preservation
and self interest if common objectives are to be
pursued in partnership with government, the public,
and industry. Unless medicine is to be relegated to a
largely technical function doctors will need to play a
more prominent and creative role in developing health
policy than hitherto and to discover a coherent voice to
articulate physicians’ values. To build the new relation›
ships necessary for this more integrated contribution,
the profession must first correct—with urgency—its his›
torical tolerance of variable practice, standards, and
outcomes.
Not only is medicine immensely diverse, but it is
backed by a vast international research effort. To secure
a more effective and imaginative harnessing of social as
well as biological and physical science, we will need to
rethink the organisation of conventional academic
medical centres and reappraise the policies of research
funding bodies.
By far the biggest challenge is to achieve a better fit
between medicine and the health problems and
aspirations of people. In a way the publication of our
book, which was created on an internet site with
comment from collaborators from far afield, momen›
tarily interrupts our experiment just when it was
getting interesting. Informal discussion with the
authors and their networks of colleagues indicated
that there are many here and abroad who are thinking
imaginatively about the future. This week, the book is
launched at a conference in London. The intention
is to bring the imaginative conjectures of clinical
investigators to the fore of thinking about the future of
health policy. We want to start a process that will
strengthen the sometimes muted voice of physicians’
values in the debate about the future development of
the NHS.
Marshall Marinker Visiting professor of general practice
Guy’s, King’s and St Thomas’s Hospitals Medical School, King’s
College, London SE11 6SP
Michael Peckham Director
School of Public Policy, University College, London WC1H 9EZ
We hope in time to see a forum of open debate on the internet
about the future contribution of medicine and doctors to
society.
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